Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyModa Health Tezspire Coverage Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentModa HealthPolicy IC-0650

    Tezepelumab (Tezspire) — Coverage Criteria for Severe Asthma

    Customize your policy alerts

    Sign up for Moda Health Policy IC-0650 alerts

    Get alerted when Policy IC-0650 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage and medical necessity criteria for subcutaneous tezepelumab (Tezspire) as add-on maintenance therapy in patients (age >=12) with severe asthma, including dosing, quantity limits, and renewal requirements for Moda Health members.

    Policy Summary
    PayerModa Health
    PolicyTezepelumab (Tezspire) — Coverage Criteria for Severe Asthma
    Policy CodePolicy IC-0650
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 2, 2023
    Next Review DateMar 2, 2023
    Key ActionObtain prior authorization demonstrating patient is ≥12 years old, meets severe asthma criteria, and is on medium-to-high dose inhaled corticosteroid plus an additional controller.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    210 mgdose per administration
    1 q4w

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    frequency / quantity limit
    6 molength of authorization
    Age ≥12minimum patient age
    J2356HCPCS code

    Coverage Criteria for Tezepelumab (Tezspire)

    Initial Therapy

    Covered when ALL of the following are met:

    Age: Patient is at least 12 years of age>=12 years
    Universal concurrent-use and indication restrictions: Will not be used in combination with other anti-IgE, anti-IL4, or anti-IL5 monoclonal antibody agents; will not be administered concurrently with live vaccines; will not be used for relief of acute bronchospasm or status asthmaticus.

    Examples of other agents include benralizumab, omalizumab, mepolizumab, reslizumab, dupilumab.

    Severity and background controller therapy: Patient has severe asthma and will be used as add-on maintenance treatment in patients regularly receiving BOTH: (1) medium- to high-dose inhaled corticosteroids AND (2) an additional controller medication (e.g., long-acting beta agonist, leukotriene modifier).

    Components of severe asthma include symptoms throughout the day, frequent nighttime awakenings, frequent SABA use, markedly limited activities, percent predicted FEV1 <60%, and more frequent/intense exacerbations.

    Exacerbation history: Either two or more exacerbations in the previous year requiring oral or injectable corticosteroid treatment (in addition to regular maintenance therapy) OR one exacerbation resulting in hospitalization.>=2 exacerbations in prior year OR >=1 hospitalization
    Baseline clinical assessment: Baseline measurement documented of at least one: systemic corticosteroid use; inhaled corticosteroid use; number of hospitalizations/ER/unscheduled visits due to asthma; or FEV1.

    Used to assess clinical status prior to initiation.

    Renewal Therapy

    Renewal (coverage may be renewed when):

    Ongoing eligibility and safety: Patient continues to meet universal and indication-specific criteria from the initial approval and has absence of unacceptable toxicity to the drug (e.g., parasitic/helminth infection, severe hypersensitivity reactions).
    Clinical benefit: Either improvement in asthma symptoms or exacerbations as evidenced by decreased use of systemic corticosteroids; a two-fold or greater decrease in inhaled corticosteroid use for at least 3 days; decreased hospitalizations, ER visits, or unscheduled visits; OR improvement from baseline in FEV1.

    Document clinical response compared with baseline measures.

    The medication must not be used in combination with other anti‑IgE, anti‑IL4, or anti‑IL5 monoclonal antibody agents (for example, benralizumab, omalizumab, mepolizumab, reslizumab, dupilumab). Additionally, concurrent administration with live vaccines is prohibited. These concurrent-use restrictions are considered universal criteria and violation of them may result in denial of coverage.

    Tezspire is not indicated for relief of acute bronchospasm or status asthmaticus. Administration for the purpose of treating an acute asthma exacerbation or status asthmaticus is explicitly not medically necessary and is excluded from coverage under this policy.

    Billing, Codes, and Quantity Limits

    Covered HCPCS CodesHCPCSCovered
    J2356Injection, tezepelumab-ekko, 1 mg; 1 billable unit = 1 mg
    NDC CodesNDCCovered
    55513-0123-xxTezspire 210 mg/1.91 mL single-dose prefilled pen
    55513-0112-xxTezspire 210 mg/1.91 mL single-dose prefilled syringe
    55513-0100-xxTezspire 210 mg/1.91 mL single-dose vial
    Covered Diagnosis CodesICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    Max dose per period — unitization
    Max dose per period210 billable units (210 mg) every 4 weeks
    Quantity limit (pen)Tezspire 210 mg single‑dose prefilled pen: 1 pen every 4 weeks
    Quantity limit (syringe)Tezspire 210 mg single‑dose prefilled syringe: 1 syringe every 4 weeks
    Quantity limit (vial)Tezspire 210 mg single‑dose vial: 1 vial every 4 weeks

    Provider Requirements and Documentation

    Prior Authorization

    Prior Authorization Required for Severe Asthma

    Prior authorization is required for treatment of severe asthma in patients aged 12 years and older. The request must document background controller therapy and disease severity, and include required baseline clinical measurements and exacerbation history. Therapy must not be used concurrently with other anti-IgE/anti-IL4/anti-IL5 biologics, with live vaccines, or for acute bronchospasm/status asthmaticus.

    • Prior authorization required for severe asthma (age ≥ 12)
    • Background controller therapy required: failure or inadequate control on medium-to-high dose inhaled corticosteroid PLUS an additional controller (e.g., long-acting beta agonist, leukotriene modifier)
    • Required clinical documentation: at least two exacerbations in the prior 12 months requiring oral/injectable corticosteroids OR one exacerbation resulting in hospitalization; baseline measures such as systemic corticosteroid use, inhaled corticosteroid use, number of hospitalizations/ER/unscheduled visits, and FEV1
    Documentation Required

    Background Controller Therapy Requirement

    Background on Tezspire

    Tezspire (tezepelumab‑ekko) is an add‑on maintenance biologic for patients with severe asthma. Use is limited by universal criteria: it must not be given concurrently with other anti‑IgE, anti‑IL4, or anti‑IL5 monoclonal antibodies, it must not be administered at the same time as live vaccines, and it is not to be used for relief of acute bronchospasm or status asthmaticus. These limitations define appropriate clinical scenarios for therapy and are required conditions for coverage.

    Definitions and Clinical Severity

    Definition of severe asthma
    Symptoms patternSymptoms throughout the day; frequent nighttime awakenings (often 7x/week); SABA use several times per day
    Activity limitationExtremely limited normal activities due to asthma
    Lung function thresholdPercent predicted FEV1 < 60%
    Exacerbation frequencyExacerbations requiring oral systemic corticosteroids are generally more frequent and intense compared with moderate asthma
    Policy Summary
    PayerModa Health
    PolicyTezepelumab (Tezspire) — Coverage Criteria for Severe Asthma
    Policy CodePolicy IC-0650
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 2, 2023
    Next Review DateMar 2, 2023
    Key ActionObtain prior authorization demonstrating patient is ≥12 years old, meets severe asthma criteria, and is on medium-to-high dose inhaled corticosteroid plus an additional controller.
    SourceLink
    On This Page
    Coverage Criteria for Tezepelumab (Tezspire)Billing, Codes, and Quantity LimitsProvider Requirements and DocumentationBackground on TezspireDefinitions and Clinical Severity

    Requests must show that the patient is receiving add-on maintenance treatment while regularly taking BOTH of the following background therapies: medium- to high-dose inhaled corticosteroids AND an additional controller medication (for example, long-acting beta agonist, leukotriene modifiers).

    • Medium- to high-dose inhaled corticosteroid documented
    • Additional controller therapy documented (e.g., LABA, leukotriene modifier)
    Documentation Required

    Required Clinical Documentation

    Clinical documentation supporting the prior authorization must include baseline assessment and response data: documentation of exacerbation history (≥2 exacerbations requiring systemic corticosteroids in prior 12 months OR ≥1 hospitalization), baseline and follow-up measures such as systemic corticosteroid use, inhaled corticosteroid use, number of hospitalizations/ER/unscheduled visits, and FEV1. For renewals, provide evidence of clinical improvement or absence of unacceptable toxicity.

    • Exacerbation history: two or more in prior year requiring oral/injectable corticosteroids OR one resulting in hospitalization
    • Baseline measurements: systemic corticosteroid use, inhaled corticosteroid use, hospitalizations/ER/unscheduled visits, FEV1
    • Renewal evidence: improved symptoms/exacerbations (reduced systemic steroid use, decreased inhaled steroid use, fewer hospitalizations/ER/unscheduled visits) OR improvement in FEV1
    • Document absence of unacceptable toxicity (e.g., parasitic infection, severe hypersensitivity)
    Denial Risk

    Contraindicated Concurrent Uses and Acute Use Limitation

    Do not authorize use when the patient will receive another anti-IgE, anti-IL4, or anti-IL5 monoclonal antibody concurrently. Do not authorize concurrent administration with live vaccines. The agent is not indicated for acute relief of bronchospasm or status asthmaticus.

    • Contraindicated concurrent uses: other anti-IgE/anti-IL4/anti-IL5 biologics (e.g., benralizumab, omalizumab, mepolizumab, reslizumab, dupilumab)
    • Do not administer concurrently with live vaccines
    • Not for acute bronchospasm or status asthmaticus